I agree my interpretation is the same as OP, this addresses the concerns and links the requirements back to the existing P3 trial data thus renedering the need for an additional trial redundant. Move on to BLA.
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD, page-93
-
- There are more pages in this discussion • 119 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
-0.020(1.78%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.13 | $1.09 | $4.556M | 4.141M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9590 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 3132 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |